Skip to content

DMT for depression: all studies

Page 2 of 4: studies 11 to 20 of 36, newest first. Back to the DMT for depression overview

Research

Immunomodulatory and behavioral effects of ayahuasca and N, N-dimethyltryptamine in a rat model of lipopolysaccharide-induced depression.

Metabolic Brain Disease June 11, 2025 Daniel do Nascimento Sousa, Monique de Azevedo, Maria Lucília Santos et al. 5 citations

Ayahuasca (Aya) is an Amazonian beverage traditionally used as medicine by Indigenous people in South America to treat various illnesses and have shown a potential to treat depression. This study aimed to investigate the antidepressant effects of fluoxetine, Aya and N, N dimethyl tryptamine (DMT), a component of the beverage, focusing on the modulation of inflammatory serum cytokine profiles...

Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and Major Depressive Disorder (MDD) patients: A systematic review of early-phase clinical trials.

Progress in neuro-psychopharmacology & biological psychiatry June 7, 2025 Damian Swieczkowski, Aleksander Kwaśny, Wiesław Jerzy Cubała 5 citations

Treatment-resistant depression (TRD) remains a challenge, with many patients unresponsive to standard antidepressants. NN-dimethyltryptamine (DMT), a fast-acting psychedelic, offers potential benefits due to its rapid onset and short duration. This review, registered with the Open Science Framework (DOI: 10.17605/OSF.IO/6D9WC), summarizes the safety and tolerability of DMT in early-phase...

DOI: 10.1016/j.pnpbp.2025.111419 (opens in new tab) Full text (opens in new tab) Nn-Dimethyltryptamine DMT Systematic review Treatment resistant depression Psychedelics hallucinogens +4

Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology May 1, 2025 Marcelo Falchi-Carvalho, Fernanda Palhano-Fontes, Isabel Wießner et al. 35 citations

Depression affects over 185 million people worldwide, with approximately one-third classified as treatment-resistant depression (TRD). Current treatments, such as oral antidepressants, often take around 3 weeks to become effective, with no immediate anti-suicidal benefits. The field urgently needs innovative therapies that provide rapid relief. Psychedelics like psilocybin and ayahuasca have...

DOI: 10.1038/s41386-025-02091-6 (opens in new tab) Full text (opens in new tab) Mental health Depression treatment Psychedelic medicine Clinical research +1

A Toad Less Traveled: Should 5-MeO-DMT Have a Role in Treating Depression?

Psychedelic Medicine April 14, 2025 Caroline Hayes

As the therapeutic potential of psychedelics is becoming more established, a wider range of compounds are beginning to be investigated for their antidepressant properties. 5-Methoxy- N , N -dimethyltryptamine (5-MeO-DMT) is one such example; its unusual properties may make it a more cost-effective and practical choice for health care providers. However, the same distinctive features may mean...

The Antidepressant Effects of Vaporized N,N-Dimethyltryptamine: An Open-Label Pilot Trial in Treatment-Resistant Depression.

Psychedelic medicine (New Rochelle, N.Y.) March 1, 2025 Marcelo Falchi-Carvalho, Handersson Barros, Raynara Bolcont et al. 16 citations

N,N-Dimethyltryptamine (DMT), a naturally occurring psychedelic tryptamine contained in the indigenous ayahuasca brew, has shown antidepressant effects. This open-label clinical trial investigates for the first time the efficacy of vaporized DMT in treatment-resistant depression (TRD). Six TRD patients participated in an open-label, fixed-order, dose-escalation study, receiving a lower (15 mg)...

Long-Term Mental Health and Wellbeing Outcomes Associated with Naturalistic Ayahuasca Consumption.

Journal of Psychoactive Drugs February 20, 2025 Broc A. Pagni, Andreas Halman, Jerome Sarris et al. 7 citations

The durability of ayahuasca's effects on mental health and the influence of clinical diagnoses on therapeutic response is unclear. Adults with no prior exposure to ayahuasca (n = 66) participating in neo-shamanic ayahuasca ceremonies completed questionnaires at baseline, 7 days, and 1, 6, and 12 months. Mixed models were used to characterize temporal trajectories in mental health, alcohol and...

Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression

American Journal of Psychiatry 2025 Johannes G. Ramaekers, Johannes T. Reckweg, Natasha L. Mason 25 citations

Unlike classical antidepressants, psychedelics such as psilocybin have been shown to induce a rapid antidepressant response. In the wake of this development, interest has emerged in ultra-fast, short-acting psychedelics such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-dimethyltryptamine (DMT) with the expectation that these can produce rapid antidepressant effects following an...

DOI: 10.1176/appi.ajp.20230890 (opens in new tab) 5-MEO-DMT Depression Psychedelic drugs Quick-onset treatment +3

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants.

Journal of psychopharmacology (Oxford, England) August 1, 2024 James Jonathan Rucker, Claire T. Roberts, Mathieu Seynaeve et al. 32 citations

To investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BPL-003, a novel intranasal benzoate salt formulation of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), in healthy participants. In all, 44 psychedelic-naïve participants enrolled in the double-blind, placebo-controlled single ascending dose study (1-12 mg BPL-003). Concentrations of 5-MeO-DMT and its...

The antidepressant effects of vaporized N,N-Dimethyltryptamine: a preliminary report in treatment-resistant depression

medRxiv January 4, 2024 Marcelo Falchi-Carvalho, Handersson Barros, Raynara Bolcont et al. 5 citations preprint

Abstract Introduction N,N-Dimethyltryptamine (DMT), a naturally occurring psychedelic tryptamine contained in the indigenous ayahuasca brew has shown antidepressant effects. This Phase 2a clinical trial investigates for the first time the efficacy of isolated DMT in treatment-resistant depression (TRD). Methods Six TRD patients participated in an open-label, fixed-order, dose-escalation study,...

Psilocybin and Other Classic Psychedelics in Depression.

Current Topics in Behavioral Neurosciences 2024 D J Nutt, Joseph Peill, B Weiss et al. 30 citations

Psychedelic drugs such as psilocybin and ketamine are returning to clinical research and intervention across several disorders including the treatment of depression. This chapter focusses on psychedelics that specifically target the 5-HT2A receptor such as psilocybin and DMT. These produce plasma-concentration related psychological effects such as hallucinations and out of body experiences,...